key: cord-0683504-fis2t02u
authors: Verreault-Julien, Louis; Rinfret, Stéphane
title: Prolonged reperfusion delays during the COVID-19 pandemic: is faster always better?
date: 2022-03-12
journal: Can J Cardiol
DOI: 10.1016/j.cjca.2022.03.007
sha: 6100a483a31f96cdb234735e7d94454859f2c036
doc_id: 683504
cord_uid: fis2t02u

nan

The treatment of ST-elevation myocardial infarction (STEMI) has evolved drastically over the last decades, moving from medical management only to fibrinolysis and finally to primary percutaneous coronary intervention (PPCI). The improvements in all aspects of the management led to decreases in hospital and longer-term mortality (1, 2) . While medical management and advances in device therapies played a crucial role, one of the key factors of treatment is widely considered to be the delay from first medical contact to opening of the culprit artery (FMC-todevice), as "time is muscle" with STEMI (3, 4) . Subgroup analyses from prior large randomized clinical trials and observational studies showed a direct relationship between reduced FMC-todevice delay and improved clinical outcomes, including a reduction in mortality (5) (6) (7) (8) . As such, all efforts have been directed towards reducing this delay, notably by creating new emergency medical services (EMS) pathways. The first regional protocol for patient transfer to a PPCIcapable center was developed in Canada (9) . Due to these new measures, FMC-to-device delays have decreased considerably over the last 15-20 years (10, 11) .

The COVID-19 pandemic brought a whole new burden to healthcare systems around the globe. The Canadian healthcare system sustained significant burnout, with COVID-19 patients occupying coronary or intensive care unit beds and healthcare workers shortage. The pandemic, in its most intense periods, limited the capacity of tertiary care hospitals to accommodate transfers, which caused treatment delays in patients with cardiac and other diseases (12) . The treatment of STEMIs, despite its emergency nature, was inevitably impacted by those factors. Many registries and meta-analyses confirmed the overall impression in cath labs around the world: the number of STEMI patients reaching the hospital and the cath lab declined, and STEMI patients' treatment was often delayed(13-18). (19) . In this study from British Columbia, the incidence of STEMI patients treated with PPCI remained the same when compared to previous years, in contrast to previously published data from Canada and other countries, which reported a reduction in those numbers (14, 15, 17, 18) . The pandemic hit British Columbia much later than other parts of Canada with a first wave in the early fall of 2020 (20) , which likely preserved the natural propensity of patients to seek medical attention when they were symptomatic with STEMI. A total of 949 STEMI patients treated during the same period of the year over the preceding 3-years the pandemic era were compared to 305 patients treated during COVID-19. Over the study period, FMC-to-device delay rose from 102 minutes to 116 minutes, a significant 14-minute increase (IQR +8 to +20 minutes) even more pronounced in patients requiring transfer to a PPCI-capable center, for which the delay went from 117 to 145 minutes, almost half an hour more (IQR +16 to +38 minutes). Comparable delays in treatment during the pandemic were also observed in previous registries and meta-analyses, with increases in door-toballoon time averaging around 10 minutes (13, 14) . Interestingly, the number of mechanical complications was the same as prior to the pandemic. However, mortality was lower by an absolute 2.4% during COVID-19. Although this difference in mortality was not significant (with a p-value of 0.18), authors could have been tempted to attribute an increase in mortality of a similar magnitude to treatment delays.

Should we be surprised that mortality was not affected by such an increase in treatment delays? Not so much. Using the CathPCI registry of the National Cardiovascular Data Registry (11) . Moreover, this finding was consistent in all subgroups, including the high-risk ones such as elderly, anterior MI and cardiogenic shock patients. In the STREAM trial that compared fibrinolysis to PPCI in patients who could not undergo PPCI within 60 minutes, randomization to a reperfusion therapy that had an inherent 78-minute delay did not cause any harm. While we should acknowledge that fibrinolysis is only successful in two thirds of patients, the study gives some clues that a reasonable delay in reperfusion might not be as harmful as previously believed (21). However, in statistical analyses, one can only control for known confounders, while unmeasured ones likely remain in the relationship between shorter reperfusion delays and reduced mortality.

Nevertheless, over the last 20 years, the FMC-to-device delay has been regarded as the primary quality-of-care metric in STEMI patients. This is reinforced in practice guidelines stating that STEMI patients should receive PPCI within 90 to 120 minutes, depending on the center at which they present (3, 4) . Everyone in cardiology believes that the sooner the occluded artery is reopened, stopping the transmural lesion current and limiting the irreversible infarct size, the better the outcomes will be. While it makes no doubt that STEMI treatment is an emergency and the benefits J o u r n a l P r e -p r o o f of PPCI over fibrinolysis is dependent on the FMC-to-device delay, taking extra minutes once PPCI has been chosen may not be as harmful as we thought (22) (23) (24) (25) (26) . While FMC-to-treatment delays are considered fundamental and dogmatic metrics for quality-of-care, one might wonder whether other more meaningful outcomes measures or care process such as risk-adjusted shortterm mortality, completeness of revascularization, or use of guideline-recommended therapies should take over in our assessment of quality-of-care in STEMI. Taking extra minutes to take a good clinical history, ruling out contra-indications, listening to the heart to rule out major murmurs, organize a safer transfer of a patient, explore alternative diagnoses, assess local resources before transfer with a nurse or a physician (and therefore avoiding harming other patients), treat pulmonary oedema, stabilize blood pressure are examples of things that take a bit of extra time but that are likely worth doing instead of rushing to meet the delay to reperfusion goals. Optimizing therapy once in-hospital is likely as important, as time to reperfusion. This involves non-infarct related artery PCI for complete revascularization, prompt recognition of mechanical complications, and up-to-date management of cardiogenic shock. With the establishment of new COVID protocols, the assessment and care of patients became unquestionably more systematic.

While the observed reduction in mortality after PCI could have been partially explained by a reduction in patients' risk profile once reaching the cath lab, the data do not support this hypothesis, with similar risk profiles of both cohorts.

Obviously and rightfully, no investigator will ever randomize patients to longer vs. shorter FMC-to-device delay. The COVID-19 pandemic gave us the unexpected natural experiment to measure the effect of a moderately prolonged FMC-to-device delays on clinical outcomes after STEMI. It is time to reassess the quality indicators of STEMI programs. Faster is not always better.

J o u r n a l P r e -p r o o f

Demographic and Regional Trends of Mortality in Patients With Acute Myocardial Infarction in the United States

Trends in Short-and Long-Term ST-Segment-Elevation Myocardial Infarction Prognosis Over 3 Decades: A Mediterranean Population-Based ST-Segment-Elevation Myocardial Infarction Registry

Canadian Cardiovascular Society/Canadian Association of Interventional Cardiology Guidelines on the Acute Management of ST-Elevation Myocardial Infarction: Focused Update on Regionalization and Reperfusion

ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with STsegment elevation of the European Society of Cardiology (ESC)

Relationship Between Delay in Performing Direct Coronary Angioplasty and Early Clinical Outcome in Patients With Acute Myocardial Infarction

Relationship of symptom-onset-to-balloon time and door-to-balloon time with mortality in patients undergoing angioplasty for acute myocardial infarction

Time delay to treatment and mortality in primary angioplasty for acute myocardial infarction: every minute of delay counts

Effect of door-to-balloon time on mortality in patients with ST-segment elevation myocardial infarction

A Citywide Protocol for Primary PCI in ST-Segment Elevation Myocardial Infarction

Trends in door-to-balloon time and mortality in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention

Door-to-balloon time and mortality among patients undergoing primary PCI

Delayed Care with Harmful Health Consequences-Reported Experiences from National Surveys During Coronavirus Disease

The Global Effect of the COVID-19 Pandemic on STEMI Care: A Systematic Review and Meta-analysis

Effect of the COVID-19 pandemic on mortality of patients with STEMI: a systematic review and meta-analysis

The COVID-19 Pandemic and Coronary Angiography for ST-Elevation Myocardial Infarction, Use of Mechanical Support, and Mechanical Complications in Canada: A Canadian Association of Interventional Cardiology National Survey

Delays in ST-Elevation Myocardial Infarction Care During the COVID-19 Lockdown: An Observational Study

Reduction in ST-Segment Elevation Cardiac Catheterization Laboratory Activations in the United States During COVID-19 Pandemic

Impact of COVID-19 outbreak on regional STEMI care in Germany

Care and Outcomes of ST-Segment-Elevation Myocardial Infarction across multiple Coronavirus Disease 2019 (COVID-19) waves

COVID-19: One Year of the Pandemic in BC

Fibrinolysis or Primary PCI in ST-Segment Elevation Myocardial Infarction

Benefit of transferring ST-segment-elevation myocardial infarction patients for percutaneous coronary intervention compared with administration of onsite fibrinolytic declines as delays increase

Does time matter? A pooled analysis of randomized clinical trials comparing primary percutaneous coronary intervention and in-hospital fibrinolysis in acute myocardial infarction patients

Comparison of mortality rates in acute myocardial infarction treated by percutaneous coronary intervention versus fibrinolysis

Percutaneous coronary intervention versus fibrinolytic therapy in acute myocardial infarction: is timing (almost) everything?

Hospital delays in reperfusion for ST-elevation myocardial infarction: implications when selecting a reperfusion strategy